Clinical Trial Search

Primary: Proportion of Subjects Achieving Complete Clearance of All Warts (Baseline and New) at the End of Study. — 0.248; 0.294; 0.09 proportion of participants

Primary: Proportion of Subjects With Complete Clearance of All Warts (Both Presented at Baseline and Newly Emerged Warts) at End of Study — 0.191; 0.272; 0.103 participants

Primary: Efficacy: Complete Clearance of Baseline External Genital and Perianal Warts at or Before Week 12 — 2; 5; 2; 10 Participants

Primary: Number of Participants With Complete Clearance, — 0; 0; 3; 5 participants

Primary: Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts at the Study Day 84 (End of Treatment) Visit. — 11; 1; 9; 0 Participants — p=0.0048

Primary: HPV DNA and HIV Status — 96; 19; 4; 5 participants

Primary: Human Papillomavirus (HPV) Types in External Genital Warts (EGW) — 80; 12.66; 0.66; 2 percentage of participants

Primary: Change in Wart Number — 0.5 warts

Primary: Change in the Maximum Size of the Genital Wart Lesion Over the Trial Period (as Measured in mm) — 8; 6; 11; 7 Participants

Primary: Number and Percentage of Subjects With Total Disappearance of All Warts Within All Treated Areas. — 100; 102; 12 Participants

Primary: Complete Clearance of Disease at Week 14 — 1; 0; 0; 0 participants — p=0.862

Primary: Base Study: Incidence of Human Papillomavirus (HPV) Type 6/11/16/18-related External Genital Warts, Penile/Perianal/Perineal Intraepithelial Neoplasia (PIN), Penile…

Primary: Percentage of Verrucae Cleared — 67.6 percentage of verrucae clearance

Primary: Female Sexual Function Index (FSFI) Score — 0.8; 1.2; 0.9; 0.7 score on a scale

Primary: Percentage of Participants With no Histologic Evidence of Anal or Anal/Peri-Anal HSIL and no Evidence of HPV-16/18 at Week 36 — 9.1 percentage of participants — p=0.8633

Primary: The Primary Efficacy Endpoint is the Number of Subjects Whose Identified Common Warts Are Determined to be Clear on the PWA Scale (PWA=0) at Visit 10 (Day 60) — 40; 13…

Primary: Proportion of Subjects With Treatment Emergent AEs After Application of A-101 45% for the Treatment of Common Warts — 70; 116 Participants

Primary: Final Response of Anal High-grade Squamous Intraepithelial Lesions (HSIL) — 3; 0; 7; 3 participants — p=.042

Primary: HPV Prevalence — 61 participants

Primary: Proportion of Patients With Regression of Perianal High-grade Squamous Intraepithelial Lesions (HSIL) — 0.515 proportion of participants

Primary: Clinical Clearance of Warts — 13; 4; 2 # of warts

Primary: The Primary Efficacy Endpoint is the Number of Subjects Whose Identified Common Warts Are Determined to be Clear on the PWA Scale (PWA=0) at Visit 10 (Day 60) — 33; 8…

Primary: Overall Response Rate at 48 Weeks — 10 Participants

Primary: Change in Total Oral Mucosal Area Covered by Warts. — 11; 2 participants — p=0.30

Primary: Mean Change in Physician's Wart Assessment Score From Baseline to Day 57 — -0.77; -0.23 score on a scale (PWA)

Primary: Incidence of HPV 6/11/16/18-related Cervical Intraepithelial Neoplasia (CIN)(Any Grade), Adenocarcinoma In Situ (AIS) or Cervical Cancer — 0; 1.2 incidence rate per 100…

Primary: Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies — 1440.4; 1903.7; 3861.7; 1397.5 EL.U/mL

Primary: Prevalence of Penile HPV Genotypes — 2.6; 0.7; 21.7; 11.6 percentage of participants

Primary: Percentage of Participants With No Histologic Evidence of Vulvar HSIL and No Evidence of HPV-16 and/or HPV-18 in Vulvar Tissue Samples — 15.0; 37.5 percentage of…

Primary: Base Study: Combined Incidence of 6-Month Persistent Infection, Cervical Intraepithelial Neoplasia (CIN+), and External Genital Lesions Related to Human Papillomavirus…